2021 Advances in Head and Neck Cancer Conference

August 21, 2021

This symposium aims to provide health care professionals with increased knowledge about the standard of care, evaluation, and treatment, as well as future directions in the management of head and neck cancers. The event will include presentations and panel discussions on squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx, HPV-positive oropharyngeal cancer, recurrent/metastatic head and neck cancer, immunotherapy in head and neck cancer treatment, and survivorship for head and neck cancer patients.

Target Audience

Medical, radiation, and surgical oncologists, otolaryngologists, audiologists, speech therapists, dentists, primary care physicians, internal medicine physicians, family practice physicians, nurse practitioners, physician assistants, nurses, and other interested health care professionals.

Learning Objectives

Upon completion of this program, attendees will:
•    Have increased knowledge regarding the standard of care evaluation and treatment of squamous cell carcinoma of the oral cavity, HPV negative oropharynx, larynx, hypopharynx, nasal cavity, paranasal sinuses, and the nasopharynx.
•    Have increased knowledge regarding the standard of care evaluation and treatment of squamous cell carcinoma of the HPV positive oropharyngeal cancer.
•    Have increased knowledge regarding the standard of care evaluation and treatment of squamous cell carcinoma of salivary gland tumors of the head and neck.

Additional Information

AttachmentSize
PDF icon Head and Neck Conference Handout.pdf243.23 KB
Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  • 7.75 Attendance
Course opens: 
06/02/2021
Course expires: 
12/31/2021
Event starts: 
08/21/2021 - 8:00am
Event ends: 
08/21/2021 - 4:40pm
Cost:
$1.00

Agenda

Morning Session

8 a.m. Keynote Presentation: Integrating Immunotherapy into
Locally Advanced Head and Neck Cancer
Robert L. Ferris, MD, PhD

9 – 10:20 a.m. Oral Cavity
Moderator: Mark Kubik, MD
• AJCC 8th Edition Staging: Implications for Oral Cancer: Shaum Sridharan, MD
• Management of the N0 Neck: Mark Kubik, MD
• Update in Oral Cavity Reconstruction: Mario Solari, MD
• Adjuvant Therapy for Oral Cancer: David (Andy) Clump MD, PhD
• Panel: Oral Cavity Cases

10:20 a.m. Break

10:25 – 11:25 a.m. Larynx and Hypopharynx
Moderator: Shaum Sridharan, MD
• Surgical Techniques for Laryngeal Cancer: Shaum Sridharan, MD
• Organ Preservation in Laryngeal/Hypopharyngeal Cancer:
Heath D. Skinner, MD, PhD
• Escalation Efforts to Improve Outcomes in HPV-Negative HNSCC:
Moon J. Fenton, MD, PhD
• Panel: Larynx/Hypopharynx Cases

11:25 a.m. Break

11:30 a.m. – 12:55 p.m. HPV Oropharynx
Moderator: Umamaheswar Duvvuri, MD, PhD
• Risk Stratification for HPV-Positive Patients: Dan P. Zandberg, MD
• Role of Robotic Surgery in the Management of Oropharyngeal Cancer:
Umamaheswar Duvvuri, MD, PhD
• De-intensification of Treatment in HPV-Positive Oropharyngeal Cancer:
Heath D. Skinner, MD, PhD
• Panel: Oropharynx Cases; includes Bhisham Chera, MD

12:55 to 1:25 p.m. Lunch Break

Afternoon Session

1:25 – 2:15 p.m. Rare Tumors in the Head and Neck:
Salivary Gland/Nasopharyngeal/Paranasal Sinuses
Moderator: Heath D. Skinner, MD, PhD
• Advances in Molecular Diagnostics for Salivary Gland Cancers:
Simion Chiosea, MD
• Surgery for Paranasal Sinus Tumors: Eric Wang, MD
• Systemic Therapy as Part of Multimodality Definitive Therapy in Nasopharyngeal
Carcinoma: Moon J. Fenton, MD, PhD
• Questions

2:15 – 2:20 p.m. Break

2:20 – 3:40 p.m. Management of Recurrent/Metastatic Head and Neck Cancers
Moderator: Dan P. Zandberg, MD
• Proper Selection of Patients with Recurrent Cancers Who May (or May Not)
Benefit from Surgical Resection: Seungwon Kim, MD, FACS
• Role of Reirradiation in the Treatment of Recurrent or Metastatic Head and Neck
Cancer: David (Andy) Clump, MD, PhD
• Systemic Options for Recurrent or Metastatic Head and Neck Cancers:
Dan P. Zandberg, MD
• Role of Palliative Care in the Management of Patients with Recurrent/Metastatic
cancers: Mamta Bhatnagar, MD
• Panel – Recurrent/Metastatic Cases

3:40 – 3:45 p.m. Break

3:45 – 4:35 p.m. Management of Patients Following Treatment for Head and Neck Cancer
Moderator: Seungwon Kim, MD, FACS
• Evidence-based Protocol for Surveillance Imaging Studies: Katie Traylor, DO
• Importance of Survivorship Care in the Post-treatment Management of Head and
Neck Cancer Patients: Marci Nilsen, PhD, RN
• Questions

4:35 p.m. End of Meeting

Live Virtual Conference

Course Directors

Umamaheswar Duvvuri, MD, PhD
Associate Professor of Otolaryngology

Seungwon Kim, MD
Associate Professor of Otolaryngology

Heath D. Skinner, MD, PhD
Associate Professor of Medicine

Dan P. Zandberg, MD
Associate Professor of Medicine

Course Presenters
Local Faculty
Mamta Bhatnagar, MD
Clinical Associate Professor of Medicine, Section of Palliative Care and Medical Ethics

Simion I. Chiosea, MD
Professor of Pathology

David Anthony (Andy) Clump, MD, PhD
Assistant Professor of Radiation Oncology

Umamaheswar Duvvuri, MD, PhD
Associate Professor of Otolaryngology
Surgical Oncology Co-leader, UPMC Hillman Cancer Center Head and Neck Cancer Program

Moon J. Fenton, MD, PhD
Medical Oncologist/Hematologist

Robert L. Ferris, MD, PhD
Associate Vice Chancellor for Cancer Research, Health Sciences
Hillman Professor of Oncology
Professor of Otolaryngology, of Immunology, and of Radiation Oncology, School of Medicine
Director, UPMC Hillman Cancer Center

Seungwon Kim, MD, FACS
Associate Professor of Otolaryngology
Director, Division of Head and Neck Surgery, Department of Otolaryngology

Mark Kubik, MD
Assistant Professor of Otolaryngology and Plastic Surgery

Marci Nilsen, PhD, RN
Assistant Professor of Acute and Tertiary Care, School of Nursing
Co-director, UPMC Head and Neck Cancer Survivorship Clinic

Heath D. Skinner, MD, PhD
Associate Professor of Radiation Oncology
Basic/Translational Research Co-leader, UPMC Hillman Cancer Center Head and Neck Cancer Program

Mario Solari, MD
Assistant Professor of Otolaryngology and Plastic Surgery

Shaum Sridharan, MD
Assistant Professor of Otolaryngology and Plastic Surgery

Katie Traylor, DO
Assistant Professor of Radiology
Director of Head and Neck Imaging

Eric Wang, MD
Associate Professor of Otolaryngology, Neurological Surgery, and Ophthalmology
Director of Education, UPMC Center for Cranial Base Surgery

Dan P. Zandberg, MD
Associate Professor of Medicine
Director, Head and Neck and Thyroid Cancer Disease Sections, Division of Hematology/Oncology
Medical Oncology Co-Leader, UPMC Hillman Cancer Center Head and Neck Cancer Program

Local faculty members are affiliated with the University of Pittsburgh School of Medicine and/or UPMC and reside in the Pittsburgh, PA. area unless otherwise identified.

Guest Faculty
Bhisham Chera, MD
Associate Professor
Associate Chair of Clinical Operations and Improvement
Director of Patient Safety and Quality
UNC School of Medicine

Faculty Disclosure:
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:
•    Bhisham Chera, MD Stockholder: Naveris
•    Umamaheswar Duvvuri, MD, PhD Consultant: Activ Surgical
•    Robert Ferris, MD, PhD Advisory Board: Achilles Therapeutics, Bristol-Myers Squibb, EMD Serono, Instil Bio, Inc., Life science Dynamics Limited, MacroGenics, Inc., Merck, Numab Therapeutics AG, OncoCyte Corporation, Pfizer, Rakuten Medical, Inc., Seagen, Inc.
Consultant: Abbvie, Aduro Biotech, Inc., Bicara Therapeutics, Inc., DermTech, Eli Lilly, Everest Clinical Research Corporation, F. Hoffman-La Roche, Ltd, Genocea Biosciences, Inc., Janssen, Kowa Research Institute, Inc., Mirati therapeutics, Inc., Nanobiotix, Novasenta, Pfizer, Sanofi, Zymeworks, Inc.
Grant/Research Support: Abbvie, Arcutis, Astra-Zeneca/Medimmune, BI, Bristol-Myers Squibb, Castle Biosciences, Dermavant, Eli Lilly, Galderma, Janssen, Merck, Novartis, Novasenta, Regeneron, Tesaro
Stockholder: Novasenta 
•    Mario G. Solari, MD Consultant: Baxter
•    Dan P. Zandberg, MD Grant/Research Support: Prelude Therapeutics, Aethlon, BICARA, Checkmate Pharmaceuticals, Eli Lilly, Glasko Smith Kline, Aduro, Bristol-Myers Squibb, Merck
Consultant: Macrogenics, Blueprint Medicines

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)
The University of Pittsburgh designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity. 

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  • 7.75 Attendance

Price

Cost:
$1.00
Please login or register to take this course.


Registration deadline: Wednesday, August 18, 2021

Tuition for physicians is $30. The conference is free for students/residents/fellows. The tuition for all other health care professionals is $20.

All cancellations must be made in writing and emailed to Brittni Prosdocimo at bittnerb@upmc.edu. Cancellations made on or before Wednesday, August 18, 2021 will be refunded. No refunds will be given for cancellations made after Wednesday, August 18, 2021.

Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by emailing bittnerb@upmc.edu.